CpG-PCR combined with sample pooling and mutant enrichment for CpG mutation screening in population studies.

نویسندگان

  • S D O'Dell
  • D J Wilson
  • P N Durrington
  • S E Humphries
  • I N Day
چکیده

1. Ablin RJ, Soanes WA, Bronson P, Witesby E. Precipitating antigens of the normal human prostate. J Reprod Fertil 1970;22:573–5. 2. Peehl DM. Prostate specific antigen role and function [Review]. Cancer 1995;75:2021–6. 3. Diamandis EP. New diagnostic applications and physiological functions of prostate-specific antigen [Review]. Scand J Clin Lab Invest 1995;55:105–12. 4. Graves HCB. Nonprostatic sources of prostate-specific antigen: a steroiddependent phenomenon? [Editorial] Clin Chem 1995;41:7–9. 5. Graves HCB, Sensabaugh GF, Blake ET. Postcoital detection of a malespecific semen protein [Letter]. N Engl J Med 1985;312:338. 6. Kabalin JN, Hornberger JC. Prostate-specific antigen is not excreted by human kidney or eliminated by routine hemodialysis. Urology 1991;37:308–10. 7. Levesque M, Hu H, D’Costa M, Diamandis EP. Prostate-specific antigen expression by various tumors. J Clin Lab Anal 1995;9:123–8. 8. Alanen KA, Kuopio T, Koskinen PJ, Nevalainen TJ. Immunohistochemical labelling for prostate-specific antigen in non-prostatic tissues. Pathol Res Pract 1996;192:233–7. 9. Mannello F, Bianchi G, Gazzanelli G. Immunoreactivity of prostate-specific antigen in plasma and saliva of healthy women [Tech Brief]. Clin Chem 1996;42:1110–1. 10. Diamandis EP, Yu H, Melegos DN. Ultrasensitive prostate-specific antigen assays and their clinical application [Opinion]. Clin Chem 1996;42:853–7. 11. Pummer K, Wirnsberger G, Purstner P, Stettner H, Wondschneider G. False positive prostate-specific antigen values in the sera of women with renal cell carcinoma. J Urol 1992;148:21–3. 12. Breul J, Pickl U, Hartung R. Prostate-specific antigen in urine. Eur Urol 1994;26:18–21. 13. Nowels K, Kent E, Rinsho K, Oyasu R. Prostate-specific antigen and acid-phosphatase reactive cells in cystitis cystica and glandularis. Arch Pathol Lab Med 1988;112:734–7. 14. Monath JR, Burkart JM, Freedman BI, Pittaway DE, Russell GB, Assimos DG. Effects of hemodialysis on prostate-specific antigen. Urology 1993;42:398– 400. 15. Morton JJ, Howe SF, Lowell JA, Stratta RJ, Taylor RJ. Influence of end-stage renal disease and renal transplantation on serum prostate-specific antigen. Br J Urol 1995;75:498–501. 16. Agha AH, Schechter E, Roy JB, Culkin DJ. Prostate-specific antigen is metabolized in liver. J Urol 1996;155:1332–5. 17. Breul J, Pickl U, Schaff J. Extraprostatic production of prostate-specific antigen is under hormonal control. J Urol 1997;157:212–3. 18. Yu H, Diamandis EP, Monne M, Croce CM. Oral contraceptive-induced expression of prostate-specific antigen in the female breast. J Biol Chem 1995;270:6615–8. 19. Zarghami N, Grass L, Diamandis EP. Steroid hormone regulation of prostatespecific antigen gene expression in breast cancer. Br J Cancer 1997;75: 579–88.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Inhibitory Effect of Coadministration of Silibinin and CpG-ODN2006 on Metastatic Characteristics (MMP-2 and TLR-9) of Hepatocarcinoma Cell Line

Background and purpose: Hepatocellular carcinoma (HCC) is a most common liver malignancy and TLR9 (Toll-like receptor) is essential for CpG DNA-induced immune responses. The aim of this study was to assess the anti-metastatic effects of combined administration of silibinin and CpG-ODN2006 on human hepatocellular carcinoma HepG-2 cell line model.  Materials and methods: Inhibitory effects of va...

متن کامل

Two Steps Methylation Specific PCR for Assessment of APC Promoter Methylation in Gastric Adenocarcinoma

Gastric Cancer (GC) is the second most common cancer in the world and a leading cause of cancer-related mortality. Methylation of promoter CpG islands (CGIs) belonging to tumor suppressor genes causes transcriptional silencing of their corresponding genes leading to carcinogenesis and other disorders. Adenomatous Polyposis Coli (APC) a tumor suppressor gene is inactivated by methylation of prom...

متن کامل

PLGA Nanospheres Loaded with Autoclaved Leishmania Major (ALM) and CpG-ODN: Preparation and in vitro Characterization

Objective(s) Several antigens, adjuvants and delivery systems have been evaluated for induction of protective immune responses against Leishmaniasis, but most of them have been inefficient. In this study, PLGA nanospheres as antigen delivery system CpG-ODN as an immunoadjuvant for increasing the immune responses against Autoclaved Leishmania major (ALM) were prepared and characterized. Materi...

متن کامل

Mammary tumor associated Hspb1 mutation and screening of eight cat populations of the world

Current research highlights the Hspb1 based screening of eight cat populations of the world to investigate the association of newly found locus within cat mammary tumors. Total 180 cats were screened on the basis of Hspb1 4 bp deletion locus (1514-1517del4) which was observed in six mammary tumor cases in Siamese cat breed. Case-control association study revealed the non-significance with P=0.2...

متن کامل

Association of CpG-SNP and 3\'UTR-SNP of WFS1 with the Risk of Type 2 Diabetes Mellitus in an Iranian Population

Type 2 diabetes mellitus (T2DM) is one of the most common multifactorial disorders in Iran. Recent genome wide association studies (GWASs), and functional studies have suggested that WFS1 may predispose individuals to T2DM. However, to date, the possible association of such variants with T2DM in Iranians remained unknown. Here, we investigated the association of the two polymorphisms of WFS1 (r...

متن کامل

Comparison of in vivo Adjuvanticity of Liposomal PO CpG ODN with Liposomal PS CpG ODN: Soluble Leishmania Antigens as a Model

Objective(s)CpG oligodeoxynucleotides (CpG ODNs) have been shown to have potent immunostimulatory adjuvant activity for a wide range of antigens. Due to susceptibility of phosphodiester CpG ODNs (PO CpG) to nuclease degradation, nuclease-resistant phosphorothioate CpG ODNs (PS CpG) were currently utilized in an in vivo model. In this study, according to some recently reported drawbacks with PS ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Clinical chemistry

دوره 44 1  شماره 

صفحات  -

تاریخ انتشار 1998